drugset / Trial / NCT03140813
An Initial Study of AZD7325 in Adults With Fragile X Syndrome
RandomizedCrossoverQuadruple-blindTreatment
Summary
This study will investigate the safety, tolerability and blood pharmacodynamics of treatment with oral administration of AZD7325 at 5 mg BID, 15 mg BID, and placebo BID, in adults with Fragile X Syndrome. The study also will also investigate measures of efficacy and biomarkers during treatment.
Timeline
- Start
- 2018-01-16
- Primary completion
- 2020-06-18
- Completion
- 2020-06-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD7325 | Small molecule | 5 mg | Oral |
| Subject | AZD7325 | Small molecule | 15 mg | Oral |